Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives $24.43 Average PT from Brokerages

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $24.4286.

A number of equities research analysts have issued reports on DAWN shares. Needham & Company LLC decreased their price target on shares of Day One Biopharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. HC Wainwright cut their price objective on Day One Biopharmaceuticals from $36.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, August 6th. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Piper Sandler lifted their price target on Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. upped their price target on Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a report on Friday, November 7th.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, CEO Jeremy Bender sold 15,894 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $8.91, for a total value of $141,615.54. Following the completion of the sale, the chief executive officer directly owned 177,165 shares of the company’s stock, valued at $1,578,540.15. This represents a 8.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Charles N. York II sold 4,062 shares of the firm’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $8.91, for a total transaction of $36,192.42. Following the completion of the sale, the chief financial officer owned 294,715 shares in the company, valued at $2,625,910.65. This represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 28,001 shares of company stock valued at $249,489 in the last 90 days. 6.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Federated Hermes Inc. acquired a new stake in shares of Day One Biopharmaceuticals during the 3rd quarter worth approximately $39,000. Ameritas Investment Partners Inc. lifted its position in Day One Biopharmaceuticals by 44.5% in the second quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock worth $48,000 after purchasing an additional 2,264 shares during the period. Quarry LP bought a new position in Day One Biopharmaceuticals in the third quarter worth $49,000. Entropy Technologies LP acquired a new stake in Day One Biopharmaceuticals during the second quarter worth $67,000. Finally, Prudential Financial Inc. bought a new stake in Day One Biopharmaceuticals in the 2nd quarter valued at $69,000. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Down 1.9%

Shares of DAWN stock opened at $8.41 on Thursday. Day One Biopharmaceuticals has a 12 month low of $5.64 and a 12 month high of $14.46. The company has a market cap of $863.51 million, a PE ratio of -5.53 and a beta of -1.25. The business’s 50 day moving average is $7.68 and its two-hundred day moving average is $7.06.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.09. Day One Biopharmaceuticals had a negative net margin of 113.53% and a negative return on equity of 32.05%. The business had revenue of $39.80 million during the quarter, compared to the consensus estimate of $38.20 million. During the same period in the prior year, the firm earned $0.38 EPS. Day One Biopharmaceuticals’s quarterly revenue was down 57.6% compared to the same quarter last year. As a group, equities analysts expect that Day One Biopharmaceuticals will post -0.72 EPS for the current fiscal year.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.